CTLA4 and glioblastoma: Although preclinical trials with anti-PD1/PDL1 blockers (nivolumab/pembrolizumab) were not favourable, their use with an anti-CTLA4 blocker (ipilimumab) significantly prolonged the survival rate in glioblastoma [14].